GT802
/ Grit Biotechnology, Vivacta Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 07, 2026
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Daishi Tian
New P1 trial • CNS Disorders • Multiple Sclerosis
1 to 1
Of
1
Go to page
1